|
|
Post by nylefty on Feb 11, 2018 15:25:17 GMT -5
www.drugdeliverybusiness.com/sales-sanofis-u-s-diabetes-biz-fall-30-q4/
Sales for Sanofi’s U.S. diabetes biz fall -30% in Q4
Shares in Sanofi (NYSE:SNY) fell today after the French pharmaceutical giant missed expectations on Wall Street with its 4th quarter and full-year financial results.
The company faced particular challenges in its diabetes business, which saw its global sales plunge -14% in Q4. Revenues for Sanofi’s diabetes unit in the U.S. fell -29.5% compared to the same period last year, thanks in part to decisions made by CVS and UnitedHealthcare to exclude Sanofi’s diabetes products from its commercial formularies.
|
|
|
|
Post by agedhippie on Feb 11, 2018 16:51:52 GMT -5
So the same problem Mannkind has - formulary exclusions by the PBMs.
That said they still had €1.22 billion ($1.5 billion) in global sales for the quarter with Lantus and Toujeo alone so I have limited sympathies.
|
|
|
|
Post by centralcoastinvestor on Feb 11, 2018 17:50:11 GMT -5
Anything that causes pain for Sanofi is good with me. They stabbed us in the back. I hope they get what’s coming to them along with the shorts. Not that I hold any grudges.  |
|
|
|
Post by akemp3000 on Feb 11, 2018 21:07:37 GMT -5
Sanofi's Brandicourt has been a disaster since he took over from Vielbacher. Good to see him failing. It's going to make the future that much sweeter!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 12, 2018 5:33:09 GMT -5
Sanofi's Brandicourt has been a disaster since he took over from Vielbacher. Good to see him failing. It's going to make the future that much sweeter! Raises the question, where did those previous sales move to? The previous customers (I assume) still need insulin. Other major insulin makers? MNKD? |
|
|
|
Post by agedhippie on Feb 12, 2018 8:56:00 GMT -5
Sanofi's Brandicourt has been a disaster since he took over from Vielbacher. Good to see him failing. It's going to make the future that much sweeter! Raises the question, where did those previous sales move to? The previous customers (I assume) still need insulin. Other major insulin makers? MNKD? Since Sanofi's big seller is Lantus and that's where the big drop was I would guess it's down to Basaglar. A combination of price reduction to retain PBMs, and replacement by Basaglar. Afrezza is a prandial insulin while Lantus is a basal so Afrezza does not replace Lantus if PBMs are looking for another basal. |
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Feb 12, 2018 11:24:43 GMT -5
So the same problem Mannkind has - formulary exclusions by the PBMs. That said they still had €1.22 billion ($1.5 billion) in global sales for the quarter with Lantus and Toujeo alone so I have limited sympathies. With former partner SNY, MNKD was dead out of the gate. Some good people but the French culture is their own worst enemy. Not much thought on SNY's part about using Afrezza as a combo therapy which would have taken a few years to make an impact but also built one hell of a moat. As fee for service goes away, outcomes will matter clinically and economically. |
|
|
|
Post by akemp3000 on Feb 12, 2018 12:09:38 GMT -5
So the same problem Mannkind has - formulary exclusions by the PBMs. That said they still had €1.22 billion ($1.5 billion) in global sales for the quarter with Lantus and Toujeo alone so I have limited sympathies. With former partner SNY, MNKD was dead out of the gate. Some good people but the French culture is their own worst enemy. Not much thought on SNY's part about using Afrezza as a combo therapy which would have taken a few years to make an impact but also built one hell of a moat. As fee for service goes away, outcomes will matter clinically and economically. "Outcomes will matter clinically and economically"...probably the reason Dr. David Kendall left Lilly to join Mannkind. Ironically, Sanofi dropping Afrezza could turn out to be the best thing that ever happened to Mannkind and the worst thing that ever happened to Sanofi. Time will tell soon enough. |
|
|
|
Post by kc on Feb 12, 2018 12:29:16 GMT -5
Wasn’t that a song?
Don’t Cry For Me Sanofi!
|
|
|
|
Post by mnholdem on Feb 12, 2018 15:54:54 GMT -5
Rock Star Rick might be able to do something with that. ;-))
|
|
